SCYNEXIS names Steven K. Burke to board as ADPKD program advances
The clinical-stage biotech added a kidney disease drug development veteran to its board as it works toward a Phase 2 study of SCY-770.
SEC filing
Latest
2 stories
Tuesday, September 22
Tuesday, August 11
Protara reports Q2 2026 results, redesigns ADVANCED-3 trial for TARA-002
Protara now plans an exploratory, multi-cohort ADVANCED-3 study and expects to complete BCG-Unresponsive cohort enrollment in the fourth quarter of 2026, with cash extending into 2028.
SEC filing